Contraceptive Progestogens and Incident Meningioma - Top-Institutions - MDSpire

Contraceptive Progestogens and Incident Meningioma

  • By

  • Nicklas Hasselblad Lundstrøm

  • Mette Hjorslev Knudgaard

  • Michael Skaarup Pedersen

  • Marie Louise Schougaard Christiansen

  • Charlotte Wessel Skovlund

  • July 2, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    EPI-PHARE (ANSM–French National Agency for Medicines and Health Products Safety/CNAM–French National Health Insurance)
    EPI-PHARE (ANSM–French National Agency for Medicines and Health Products Safety/CNAM–French National Health Insurance)

    Saint-Denis, Île-de-France

    Key Differentiators

    • Pharmacoepidemiology
    • Gynecology

  • #2

    Assistance Publique–Hôpitaux de Paris (AP‑HP) – Bicêtre Hospital, Department of Medical Gynecology
    Assistance Publique–Hôpitaux de Paris (AP‑HP) – Bicêtre Hospital, Department of Medical Gynecology

    Le Kremlin-Bicetre, Île-de-France

    Key Differentiators

    • Gynecology
    • Neurosurgery

  • #3

    Sidney Kimmel Comprehensive Cancer Center
    Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland

    Key Differentiators

    • Oncology
    • Neurosurgery

  • #4

    European Organisation for Research and Treatment of Cancer
    European Organisation for Research and Treatment of Cancer

    Brussels, Belgium

    Key Differentiators

    • Clinical Research
    • Oncology

  • #5

    Technical University of Munich
    Technical University of Munich

    Munich, Bavaria

    Key Differentiators

    • Radiation Oncology
    • Neurosurgery

Original Source(s)

Contraceptive Progestogens and Incident Meningioma

  • by Nicklas Hasselblad Lundstrøm, Mette Hjorslev Knudgaard, Michael Skaarup Pedersen, Marie Louise Schougaard Christiansen, Charlotte Wessel Skovlund

  • July 2, 2026

Related Content

ERCC6L in human cancers: oncogenic functions, molecular mechanisms, and clinical implications as a prognostic biomarker and therapeutic target

Robot-assisted laparoscopic resection of giant pelvic solitary fibrous tumor: a case report with literature review

ASCO26: Sara Tolaney, MD, MPH, ASCENT-04

Dana-Farber Cancer Institute's Dr. Sara Tolaney presented a subgroup analysis of the ASCENT-04 study based on biomarkers. Across all subgroups, patients who received sacituzumab govitecan plus pembro as first-line therapy had longer progression-free survival compared to standard therapy.

  • July 1, 2026

  • 1 min